Pharmacist dispensing of mifepristone: An opinion of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy

Author:

Rafie Sally1,Majerczyk Daniel2ORCID,Cieri‐Hutcherson Nicole3ORCID,Campbell Nicole4ORCID,Stone Rebecca5ORCID,Leader Lauren D.6ORCID,Weddendorf Elizabeth7,McBane Sarah8,Karaoui Lamis R.9,Herman Alexandra10,Kaczmarski Katie11

Affiliation:

1. Department of Pharmacy University of California San Diego Health San Diego California USA

2. Department of Clinical and Administrative Sciences Roosevelt University, College of Science, Health and Pharmacy Schaumburg Illinois USA

3. Department of Pharmacy Practice University at Buffalo Buffalo New York USA

4. Department of Pharmacy Practice Fairleigh Dickinson University Teaneck New Jersey USA

5. Department of Clinical and Administrative Pharmacy University of Georgia Athens Georgia USA

6. Department of Pharmacy Mary Birch Hospital for Women and Newborns San Diego California USA

7. Department of Pharmacy, University of North University of North Carolina Chapel Hill Chapel Hill North Carolina USA

8. Department of Clinical Pharmacy Practice UC Irvine School of Pharmacy and Pharmaceutical Sciences Irvine California USA

9. Department of Pharmacy Practice Lebanese American University School of Pharmacy Byblos Lebanon

10. Department of Pharmacy Practice and Administrative Sciences University of New Mexico Albuquerque New Mexico USA

11. Department of Pharmacy Practice University of Illinois at Chicago Chicago Illinois USA

Abstract

AbstractA rising percentage of patients are electing medication abortion over procedural abortion for increased safety and privacy. Access to medication abortion is essential healthcare, but many Americans face unsurmountable barriers when pursuing this option. This has been in large part due to unnecessary restrictions imposed by the United States Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, used in combination with misoprostol for medication abortion. Moreover, many states have imposed additional restrictions on abortion, further impeding access to care. Since its original approval in 2000, mifepristone can only be prescribed by certified prescribers. Until recently, mifepristone could only be dispensed by certified prescribers, whereby more accessible community and mail‐order pharmacies were prohibited from dispensing mifepristone. During the Coronavirus disease 2019 public health emergency, there was a temporary allowance for certified prescribers to utilize mail or mail‐order pharmacies to deliver medications to patients. In January 2023, the FDA approved modifications to the mifepristone REMS to allow certified pharmacies to dispense the medication. Given the established safety and effectiveness of mifepristone, the evidence supports its distribution via pharmacies and leveraging pharmacists to expand medication abortion access. Pharmacists are one of the most widely accessible healthcare providers and their responsibility centers on patient and medication safety and improving health outcomes. This article, an opinion of the American College of Clinical Pharmacy Women's Health Practice and Research Network, adds the voice of members of the pharmacy profession to the collective efforts to ensure access to medication abortion, including pharmacist dispensing of mifepristone. We encourage pharmacists to embrace this fresh opportunity to provide medication abortion care in their communities.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacy

Reference61 articles.

1. Mifepristone (RU 486) in the United States -- What Does the Future Hold?

2. Medical abortion regimens: Historical context and overview

3. U.S. Food and Drug Administration.Mifeprex (mifepristone) information.2023[cited 2023 May 23]. Available from:https://www.fda.gov/drugs/postmarket‐drug‐safety‐information‐patients‐and‐providers/mifeprex‐mifepristone‐information

4. Abortion Incidence and Service Availability in the United States, 2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3